Antimicrobial Resistance Could Lead To 40 Million Deaths By 2050, New Study Reveals

Antimicrobial resistance (AMR), a growing global health crisis, may lead to a staggering increase in deaths by 2050, according to a recent study published in The Lancet. The research projects that over the next few decades, AMR could cause more than 39 million deaths worldwide.

AMR’s Looming Threat

The study, which analyzes data from 1990 to 2021, underscores the escalating burden of AMR. It predicts that, without significant interventions, deaths attributable to AMR could reach 1.9 million annually by 2050. This dire forecast highlights the critical need for enhanced strategies to combat resistant pathogens.

Current Trends and Projections

Dr. Chris Murray, lead author and director of the Institute for Health Metrics and Evaluation at the University of Washington, emphasized the urgency of addressing AMR. “We need appropriate attention on new antibiotics and antibiotic stewardship so that we can address what is really quite a large problem,” Murray stated.

The study found contrasting trends in AMR impact across different age groups. Deaths from AMR among children under five have declined by over 50% due to advancements in vaccination and sanitation. However, there has been an alarming 80% increase in AMR-related deaths among adults aged 70 and older, a trend expected to continue as the global population ages.

Impact of Superbugs

Methicillin-resistant Staphylococcus aureus (MRSA) has been identified as a major contributor to the increasing AMR burden. The number of deaths attributable to MRSA nearly doubled from 57,200 in 1990 to 130,000 in 2021. This increase reflects the broader trend of rising resistance among various pathogens.

The study’s forecasts suggest three scenarios: a continuation of current conditions, development of new antibiotics, and improvements in healthcare quality. The most optimistic scenario, involving enhanced healthcare and access to new treatments, could prevent 92 million deaths between 2025 and 2050.

Geographic Disparities

The study reveals that regions like South Asia, Latin America, and sub-Saharan Africa face the highest burden of AMR. Many of these areas lack adequate healthcare resources, exacerbating the impact of resistant infections. “There are still, unfortunately, a lot of places in low-resource settings where people who need antibiotics are just not getting them,” Murray said.

Call to Action

Samuel Kariuki of the Kenya Medical Research Institute, in a commentary accompanying the study, stressed the need for targeted action to address AMR. “These data should drive investments and targeted action toward addressing the growing challenge of antimicrobial resistance in all regions of the world,” Kariuki advised.

Dr. Steffanie Strathdee, who has personal experience with AMR through her husband’s battle with a superbug, highlighted the potential of phage therapy. “The most important alternative to antibiotics is phage therapy, or bacteriophage therapy, and that’s what saved my husband’s life,” she said. Phage therapy could provide a critical tool in managing resistant infections.

Hope for the Future

Despite the grim projections, Strathdee remains hopeful. “If we were to scale up these interventions, we could dramatically reduce the number of deaths in the future,” she asserted. The study calls for comprehensive efforts to improve access to antibiotics, develop new medications, and enhance global healthcare infrastructure to combat the growing threat of antimicrobial resistance.

(Includes inputs from online sources)

ALSO READ: New COVID XEC Variant Spreading Rapidly Across Europe, Experts Warn